Canada markets close in 4 hours 10 minutes

Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
2.090+0.100 (+5.03%)
At close: 03:56PM HKT

Shanghai Bio-heart Biological Technology Co., Ltd.

Building 4
Room 302, 3rd Floor No.590 Ruiqing Road East Zhangjiang Hi-Tech Park, Pudong New Area
Shanghai
China
86 21 6879 8511
https://www.bio-heart.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees32

Key Executives

NameTitlePayExercisedYear Born
Mr. Li WangExecutive Chairman of the Board, CEO & GM777.73kN/A1968
Mr. Yunqing WangCFO, Joint Company Secretary & Executive Director1.29MN/A1985
Ms. Peili WangFinancial Manager & Executive Director829.36kN/A1984
Dr. Bradley Stewart Hubbard D.V.M., DVMChief Medical OfficerN/AN/A1959
Ms. Siu Ying KwokJoint Company SecretaryN/AN/A1985
Mr. Tao CaiChairperson of the Board of Supervisors & Head of Technology of BRS177.96kN/A1987
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. It develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Corporate Governance

Shanghai Bio-heart Biological Technology Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.